What is Prime Medicine's EPS (basic)?

Prime Medicine (PRME) reported EPS (basic) of -$0.28 in Q1 2026.

How has Prime Medicine's EPS (basic) changed year-over-year?

Prime Medicine's EPS (basic) increased by 30.0% year-over-year, from -$0.40 to -$0.28.

What is the long-term trend for Prime Medicine's EPS (basic)?

Over 2 years (2023 to 2025), Prime Medicine's EPS (basic) has grown at a -20.7% compound annual growth rate (CAGR), from -$2.18 to -$1.37.

What does EPS (basic) mean?

Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Prime Medicine PRME EPS (Basic)

EPS (Basic) at other companies

Eli LillyLLY

$8.27+169%

Vertex PharmaceuticalsVRTX

$4.06+61.1%

Intellia TherapeuticsNTLA

-$0.81+26.4%

CRISPR TherapeuticsCRSP

-$1.28+19.0%

Beam TherapeuticsBEAM

-$0.91+26.0%

RegenxbioRGNX

-$1.72-1,533%

Other financials

Income statement

See full

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

See full

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

See full

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

See full

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

See full

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

See full

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Prime Medicine's EPS (basic)?: Prime Medicine (PRME) reported EPS (basic) of -$0.28 in Q1 2026.
How has Prime Medicine's EPS (basic) changed year-over-year?: Prime Medicine's EPS (basic) increased by 30.0% year-over-year, from -$0.40 to -$0.28.
What is the long-term trend for Prime Medicine's EPS (basic)?: Over 2 years (2023 to 2025), Prime Medicine's EPS (basic) has grown at a -20.7% compound annual growth rate (CAGR), from -$2.18 to -$1.37.
What does EPS (basic) mean?: Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.